Iodine: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   ICU   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -10% 1 141 Improvement, Studies, Patients Relative Risk Mortality -10% 1 141 Ventilation 34% 1 141 ICU admission 30% 1 141 RCTs -10% 1 141 Late -10% 1 141 Iodine for COVID-19 c19early.org February 2026 Favorsiodine Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) -10% 1.10 [0.55-2.21] death 13/67 13/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Late treatment -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk All studies -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk 1 iodine COVID-19 study c19early.org February 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Effect extraction pre-specified(most serious outcome) Favors iodine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) -10% 1.10 [0.55-2.21] 13/67 13/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Late treatment -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk All studies -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk 1 iodine COVID-19 mortality result c19early.org February 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Favors iodine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) 34% 0.66 [0.25-1.72] 6/67 10/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment 34% 0.66 [0.25-1.72] 6/67 10/74 34% lower risk All studies 34% 0.66 [0.25-1.72] 6/67 10/74 34% lower risk 1 iodine COVID-19 mechanical ventilation result c19early.org February 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Favors iodine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) 30% 0.70 [0.29-1.71] 7/67 11/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment 30% 0.70 [0.29-1.71] 7/67 11/74 30% lower risk All studies 30% 0.70 [0.29-1.71] 7/67 11/74 30% lower risk 1 iodine COVID-19 ICU result c19early.org February 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Favors iodine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) -10% 1.10 [0.55-2.21] death 13/67 13/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Late treatment -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk All studies -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk 1 iodine COVID-19 Randomized Controlled Trial c19early.org February 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Effect extraction pre-specified(most serious outcome) Favors iodine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) -10% 1.10 [0.55-2.21] 13/67 13/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Late treatment -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk All studies -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk 1 iodine COVID-19 RCT mortality result c19early.org February 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Favors iodine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) -10% 1.10 [0.55-2.21] death 13/67 13/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Late treatment -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk All studies -10% 1.10 [0.55-2.21] 13/67 13/74 10% higher risk 1 iodine COVID-19 peer reviewed studies c19early.org February 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.79 Effect extraction pre-specified(most serious outcome) Favors iodine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Traksel (RCT) -10% 1.10 [0.55-2.21] death 13/67 13/74 Improvement, RR [CI] Treatment Control Traksel (RCT) 34% 0.66 [0.25-1.72] ventilation 6/67 10/74 Traksel (RCT) 30% 0.70 [0.29-1.71] ICU 7/67 11/74 Iodine COVID-19 outcomes c19early.org February 2026 Favors iodine Favors control